Castle Biosciences, Inc. (CSTL)Healthcare | Diagnostics & Research | Friendswood, United States | NasdaqGM
22.98 USD
-0.74
(-3.120%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 22.77 -0.21 (-0.210%) ⇩ (July 13, 2026, 7:47 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:42 a.m. EDT
The investment case for Castle Biosciences remains fundamentally broken despite a recent price bounce. The company is generating negative earnings and negative operating margins, with revenue contracting by nearly 5%. While the balance sheet appears healthy with substantial cash reserves, the business is failing to execute on growth, making it a poor candidate for long-term capital appreciation. The recent price action shows a recovery from multi-year lows, yet the underlying fundamentals—specifically the lack of profitability and shrinking top line—prevent a shift to a 'buy' rating. The options market confirms this tension: traders are buying deep out-of-the-money calls for a moonshot scenario while hedging against a drop to much lower levels, rather than betting on a steady climb. With no dividend to provide income and a weak statistical forecast, the security sits in a neutral zone where the risk of further deterioration outweighs the potential for a turnaround. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.117860 |
| AutoARIMA | 0.133351 |
| AutoETS | 0.134715 |
| AutoTheta | 0.137570 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.328 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.959 |
| Revenue per Share | 11.599 |
| Market Cap | 696,982,272 |
| Forward P/E | -24.62 |
| Beta | 1.00 |
| Profit Margins | -3.78% |
| Website | https://castlebiosciences.com |
As of July 11, 2026, 4:42 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (15 and 20), suggesting a fear of a downside gap or continued weakness. Conversely, call interest is concentrated far out-of-the-money (55 and 60 strikes), indicating a speculative bet on a massive, unlikely surge rather than a measured rally. Implied volatility is elevated on near-term puts, reflecting uncertainty about immediate support levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.21641028 |
| Address1 | 1,500 W. Parkwood Ave |
| Address2 | Suite 400 |
| All Time High | 107.69 |
| All Time Low | 9.26 |
| Ask | 28.85 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 352,500 |
| Average Daily Volume3 Month | 396,324 |
| Average Volume | 396,324 |
| Average Volume10Days | 352,500 |
| Beta | 0.996 |
| Bid | 16.65 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 15.23 |
| City | Friendswood |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.98 |
| Current Ratio | 6.745 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 23.875 |
| Day Low | 22.46 |
| Debt To Equity | 7.959 |
| Display Name | Castle Biosciences |
| Earnings Call Timestamp End | 1,785,441,600 |
| Earnings Call Timestamp Start | 1,785,441,600 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,785,441,600 |
| Earnings Timestamp Start | 1,785,441,600 |
| Ebitda | -18,353,000 |
| Ebitda Margins | -0.053990003 |
| Enterprise To Ebitda | -25.719 |
| Enterprise To Revenue | 1.389 |
| Enterprise Value | 472,021,312 |
| Eps Current Year | -1.40444 |
| Eps Forward | -0.93333 |
| Eps Trailing Twelve Months | -0.42 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.6742 |
| Fifty Day Average Change | 1.3057995 |
| Fifty Day Average Change Percent | 0.06024672 |
| Fifty Two Week Change Percent | 21.641027 |
| Fifty Two Week High | 44.28 |
| Fifty Two Week High Change | -21.3 |
| Fifty Two Week High Change Percent | -0.4810298 |
| Fifty Two Week Low | 14.59 |
| Fifty Two Week Low Change | 8.389999 |
| Fifty Two Week Low Change Percent | 0.57505137 |
| Fifty Two Week Range | 14.59 - 44.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,564,061,400,000 |
| Float Shares | 26,790,143 |
| Forward Eps | -0.93333 |
| Forward P E | -24.621515 |
| Free Cashflow | 12,890,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 942 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.77884 |
| Gross Profits | 264,742,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02728 |
| Held Percent Institutions | 0.92401004 |
| Implied Shares Outstanding | 30,329,952 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. |
| Long Name | Castle Biosciences, Inc. |
| Market | us_market |
| Market Cap | 696,982,272 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_60295846 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -12,832,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 719,426,461 |
| Number Of Analyst Opinions | 9 |
| Open | 23.785 |
| Operating Cashflow | 48,254,000 |
| Operating Margins | -0.21997 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 866 788 9007 |
| Post Market Change | -0.20999908 |
| Post Market Change Percent | -0.91383415 |
| Post Market Price | 22.77 |
| Post Market Time | 1,783,986,470 |
| Previous Close | 23.72 |
| Price Eps Current Year | -16.362392 |
| Price Hint | 2 |
| Price To Book | 1.508864 |
| Price To Sales Trailing12 Months | 2.0504303 |
| Profit Margins | -0.037750002 |
| Quick Ratio | 6.26 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.74 |
| Regular Market Change Percent | -3.11973 |
| Regular Market Day High | 23.875 |
| Regular Market Day Low | 22.46 |
| Regular Market Day Range | 22.46 - 23.875 |
| Regular Market Open | 23.785 |
| Regular Market Previous Close | 23.72 |
| Regular Market Price | 22.98 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 269,897 |
| Return On Assets | -0.03965 |
| Return On Equity | -0.02846 |
| Revenue Growth | -0.049 |
| Revenue Per Share | 11.599 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 30,329,952 |
| Shares Percent Shares Out | 0.049200002 |
| Shares Short | 1,491,750 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,484,771 |
| Short Name | Castle Biosciences, Inc. |
| Short Percent Of Float | 0.0504 |
| Short Ratio | 3.95 |
| Source Interval | 15 |
| State | TX |
| Symbol | CSTL |
| Target High Price | 52.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 43.55556 |
| Target Median Price | 43.0 |
| Total Cash | 261,684,992 |
| Total Cash Per Share | 8.628 |
| Total Debt | 36,724,000 |
| Total Revenue | 339,920,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 28.73835 |
| Two Hundred Day Average Change | -5.7583504 |
| Two Hundred Day Average Change Percent | -0.20037164 |
| Type Disp | Equity |
| Volume | 269,897 |
| Website | https://castlebiosciences.com |
| Zip | 77,546 |